RenovoRx Affirms FY2026 Sales Guidance of $3.750M-$4.250M vs $3.873M Est
Benzinga Newsdesk 2 hours ago
NewsGuidance
RenovoRx (NASDAQ:RNXT) affirms FY2026 sales outlook from $3.750 million-$4.250 million to $3.750 million-$4.250 million vs $3.873 million estimate.
RenovoRx (NASDAQ:RNXT) affirms FY2026 sales outlook from $3.750 million-$4.250 million to $3.750 million-$4.250 million vs $3.873 million estimate.